EP2346806B1 - Verfahren zur herstellung von vitamin k2 - Google Patents

Verfahren zur herstellung von vitamin k2 Download PDF

Info

Publication number
EP2346806B1
EP2346806B1 EP09785160.4A EP09785160A EP2346806B1 EP 2346806 B1 EP2346806 B1 EP 2346806B1 EP 09785160 A EP09785160 A EP 09785160A EP 2346806 B1 EP2346806 B1 EP 2346806B1
Authority
EP
European Patent Office
Prior art keywords
compound
formula
mmol
iii
naphthoquinone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP09785160.4A
Other languages
English (en)
French (fr)
Other versions
EP2346806A1 (de
Inventor
Lars Skattebol
Ingger Riedun Aukrust
Marcel Sandberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kappa Bioscience AS
Original Assignee
Kappa Bioscience AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39952163&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2346806(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kappa Bioscience AS filed Critical Kappa Bioscience AS
Priority to PL09785160T priority Critical patent/PL2346806T3/pl
Priority to DK15193746.3T priority patent/DK3018116T3/da
Priority to PL15193746T priority patent/PL3018116T3/pl
Priority to EP15193746.3A priority patent/EP3018116B1/de
Publication of EP2346806A1 publication Critical patent/EP2346806A1/de
Application granted granted Critical
Publication of EP2346806B1 publication Critical patent/EP2346806B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C46/00—Preparation of quinones
    • C07C46/02—Preparation of quinones by oxidation giving rise to quinoid structures
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00—Preparation of halogenated hydrocarbons
    • C07C17/093—Preparation of halogenated hydrocarbons by replacement by halogens
    • C07C17/16—Preparation of halogenated hydrocarbons by replacement by halogens of hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C21/00—Acyclic unsaturated compounds containing halogen atoms
    • C07C21/02—Acyclic unsaturated compounds containing halogen atoms containing carbon-to-carbon double bonds
    • C07C21/215—Halogenated polyenes with more than two carbon-to-carbon double bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
    • C07C41/22—Preparation of ethers by reactions not forming ether-oxygen bonds by introduction of halogens; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
    • C07C41/26—Preparation of ethers by reactions not forming ether-oxygen bonds by introduction of hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
    • C07C41/30—Preparation of ethers by reactions not forming ether-oxygen bonds by increasing the number of carbon atoms, e.g. by oligomerisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/215—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C46/00—Preparation of quinones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C46/00—Preparation of quinones
    • C07C46/02—Preparation of quinones by oxidation giving rise to quinoid structures
    • C07C46/04—Preparation of quinones by oxidation giving rise to quinoid structures of unsubstituted ring carbon atoms in six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/10—Quinones the quinoid structure being part of a condensed ring system containing two rings
    • C07C50/14—Quinones the quinoid structure being part of a condensed ring system containing two rings with unsaturation outside the ring system, e.g. vitamin K1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • This application relates to the synthesis of a compound that forms part of vitamin K2, as well as the synthesis of some novel intermediate compounds.
  • Vitamin K denotes a group of lipophilic and hydrophobic vitamins that are needed for the post-translational modification of certain proteins, mostly required for blood coagulation. Chemically they are 2-methyl-1,4-naphthoquinone derivatives.
  • Vitamin K is not a single compound, rather it is a series of related analogues.
  • Vitamin K1 is called phylloquinone and has the systematic name all-E-2-methyl-3-(3,7,11,15-tetramethylhexadec-2-enyl)naphthalene-1,4-dione.
  • Vitamin K2 (menaquinone) is normally produced by bacteria in the intestines, and dietary deficiency is extremely rare unless the intestines are heavily damaged or are unable to absorb the molecule.
  • Vitamin K2 is a mixture of different molecules based on a naphthoquinone structure and varying lengths of isoprenoid chains.
  • the compound MK-7 i.e. 7 isoprenyl groups
  • Menaquinones have side chains composed of all-E polyprenyl residues; generally they are designated as MK-n, where n specifies the number of isoprenoid repeating units. The minimum value of n is 2.
  • All members of the vitamin K group of vitamins share a methylated naphthoquinone ring structure, and vary in the aliphatic side chain attached at the 3-position.
  • the naphthoquinone is the main functional group of the vitamin, so that the mechanism of action is similar for all K-vitamins. Substantial differences may be expected, however, with respect to intestinal absorption, transport, tissue distribution, and bio-availability when variations in the side chain take place. These differences are caused by the different lipophilicity of the various side chains and by the different food matrices in which they occur.
  • vitamin K2 occurs naturally in various vegetables and can be produced by bacteria in the intestines, it is still an interesting synthetic target as isolation of the vitamin from a natural source is complex and concentrations of the vitamin are low. Moreover, synthesis allows the preparation of particular menaquinones rather than the isolation of a mixture of different menaquinones.
  • menaquinone compounds which form part of vitamin K2 or components thereof.
  • the first synthesis of menaquinones reported by Isler et al., Helv. Chim Acta 1958,41, 786-807 , used a nonstereospecific approach. Tso and Chen , J Chem Res 1995, 104-105 describes a one pot synthesis of vitamin K although he concentrates on the formation of the naphthoquinone ring as opposed to the side chain of the molecule. His chemistry involves the reaction of 3-substituted isobenzofuranones with vinylic sulphones to form the naphthoquinone ring structure.
  • the present inventors have devised a synthetic strategy for the formation of MK-7 and other menaquinones.
  • the method utilises Kumada or Suzuki chemistry to connect a side chain to the naphthoquinone ring.
  • the side chain can be further manipulated, e.g. using Biellmann chemistry to produce the desired compounds.
  • the process of the invention allows formation of menaquinones in high yield and crucially with stereochemical integrity.
  • the inventors do not see any presence of Z-isomers during their reactions.
  • the invention provides a process for the preparation of a compound of formula (I) comprising a step in which (i) a compound of formula (II) is reacted with a compound of formula (III) wherein R is an alkyl group; LG is a leaving group; m is an integer of from 0 to 8; n is an integer of from 0 to 9; and X is hydrogen, halide, hydroxyl, or protected hydroxyl; in the presence of a palladium catalyst.
  • the invention provides a process for the preparation of a compound of formula (I) comprising a step in which (i) a compound of formula (IV) where R is an alkyl group; is reacted with a compound of formula (III) wherein LG is a leaving group, m is an integer of from 0 to 8, n is 0 to 9 and X is hydrogen, halide, hydroxyl, or optionally protected hydroxyl; in the presence of a Pd (0) catalyst.
  • reaction of a compound of formula (II) or (IV) with a compound of formula (III) may however be only one step in the formation of a compound of formula (I).
  • the reaction of compounds (II) and (III) or (II) and (IV) yields the compound (I')
  • the process of the invention may therefore incorporate further steps before or after the claimed reaction as described below in order to allow the formation of a compound of formula (I), especially MK-7.
  • a polyprenyl side chain is one which derives from the polymerisation of isoprene: 2-methyl-1,3-butadiene.
  • an alkyl group can contain 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, especially methyl or ethyl.
  • R is preferably methyl.
  • Halide (Hal) includes fluoro, chloro, bromo and iodo, preferably chloro or bromo.
  • Halides employed as Grignard reagents are preferably bromo.
  • protecting group covers any known protecting group for the group in question.
  • Hydroxyl protecting groups include acetyl (Ac), benzyl, ⁇ -methoxyethoxymethyl ether (MEM), methoxymethyl ether (MOM), p-methoxybenzyl ether (PMB), methylthiomethyl ether, pivaloyl (Piv), tetrahydropyran (THP), Silyl ether (most popular ones include trimethylsilyl (TMS), t-butyldimethylsilyl (TBDMS), and triisopropylsilyl (TIPS) ethers), and methyl ethers.
  • preferred protecting groups are benzyl or THP.
  • leaving group is well known in the art and denotes an atom or group of atoms that readily leaves a molecule due to the relative stability of the ion formed.
  • Useful leaving groups include halides, tosylates, mesylates and triflates. In any embodiment of the invention, preferred leaving groups are halides.
  • n is 0 to 9, preferably 1 to 8, more preferably 4 to 7, e.g. 6, 7 or 8 isoprenoid units. In some embodiments n may range from 0 to 10 or 0 to 11.
  • m is 0 to 8, e.g. 0 to 7, preferably 0 to 5, more preferably 1 to 4, e.g. 2, 3 or 4 isoprenoid units. It will be appreciated that the sum of the various m values of the starting materials will add up to the value of n in the compound of formula (I) taking into account any units formed in the reactions in question. Thus if one isoprene unit is formed by the reactions then n-1 is the total of all m's. Where a reaction process involves multiple reactants in which the variable m is present, it will be appreciated that each m can be different.
  • X is preferably hydrogen.
  • the present invention relates to the synthesis of compounds of formula (I), i.e. menaquinone derivatives having varying length of a polyprenyl side chain in their backbone. Whilst the length of the polyprenyl chain in the compound of formula (I) can vary, it is preferred if there are at least 6 isoprenoid units, more preferably at least 7 isoprenoid units in the compound of formula (I). It is preferred therefore if n is at least 3, preferably 4, 5 or 6.
  • the compound of formula (III) required to effect the reaction above can contain different numbers of isoprenoid units.
  • the compound of formula (III) is typically not commercially available and itself needs to be synthesised from compounds with a smaller number of isoprenoid units.
  • a particular challenge faced by the synthetic chemist is preparing menaquinone compounds having different numbers of isoprenoid units. In order to manufacture higher menaquinones, i.e. those of 7 isoprenoid units or more, it is normally necessary to have at least one reactant which comprises 4 or more isoprenoid units. Such compounds are still not readily available and therefore need to be synthesised themselves. It will be seen therefore that the synthesis of higher menaquinones is not simple.
  • Biellmann chemistry as described in the third aspect of the invention, provides an ideal way to make even longer vitamin K2 side chain molecules which can then be coupled to a naphthoquinone ring following the chemistry described in the first and second aspects described above.
  • this chemistry can be used to increase the size of a side chain already attached to the naphthoquinone ring.
  • the most common starting materials for the formation of the isoprenoid side chains are polyprenyl alcohols. It is possible to convert an alcohol into a better leaving group and effect addition of the phenythio or phenylsulfonyl group via a nucleophilic attack of the thiophenyl ion or phenylsulfonyl- ion on the leaving group.
  • phenylthio group the inventors have found another method based on the reaction of the alcohol directly with diphenyldisulfide in the presence of a trialkyl phosphine, e.g. PBu 3 .
  • Suitable bases include BuLi.
  • Scheme 1 examplifies this type of reaction with a bromide and a phenylthio substituted derivative.
  • the bromide reactant in scheme 1 can be conveniently synthesised from farnesol (A). Protection of farnesol with a benzyl group allows the introduction of a terminal OH group using selenium dioxide in t-butylperoxide. This can then be converted to the bromide using known chemistry (scheme 2)
  • reduction of the phenythio or phenylsulfonyl group also simultaneously removes any protection present, e.g. the benzyl protecting group leaving an alcohol.
  • Reduction is conveniently effected using lithium metal in an amine solvent such as propylamine or ethylamine or using palladium catalysis with a borohydride, e.g. PdCl 2 (dppp) and lithium triethyl borohydride. Any other method for reduction of the phenythio or phenylsulfonyl group could also be employed.
  • the naphthoquinone group must be introduced.
  • This compound can be prepared from commercially available 2-methylnaphtoquinone as starting material as outlined in scheme 3.
  • This brominated intermediate is converted to its dimethoxy analogue using tin dichloride in ethanol and subsequent treatment with dimethylsulphate and base.
  • This dimethoxy derivative can then form the corresponding Grignard reagent.
  • This chemistry is well established ( Snyder and Rapoport, J Am Chem. Soc 1974, 96, 8046-8054 ).
  • the alcohol XV is converted to a halide, but the subsequent coupling to the naphthoquinone derivative using a classical Grignard reaction is not very useful. It is highly preferred if the reaction of the naphthoquinone derivative with the isoprenyl side chain is effected by Kumada coupling chemistry, as described in the first aspect of the invention.
  • Kumada chemistry improves yields and again prevents any loss of stereochemistry during the formation of the menaquinone.
  • the coupling proceeds smoothly and the menaquinone MK-7 was obtained after oxidation of the methoxy groups on the naphthoquinone ring by cerium ammonium nitrate (CAN) or other oxidation methods (scheme 4).
  • the catalyst used in the Kumada coupling can be tetrakis(triphenylphosphine)palladium(0).
  • Kumada chemistry see Yamamura, M., Moritani, 1. and Murahashi, S-1. Journal of Organometallic Chemistry, 91 (2), 1975, C39-C42 .
  • the Kumada coupling is actually used twice as outlined in scheme 5.
  • the Grignard reagent reacts with commercially available geranyl chloride providing the geranyl substituted derivative. Oxidation with SeO 2 affords the alcohol which is transformed into the bromide.
  • the second Kumada coupling between this bromide and the Grignard reagent from pentaisoprenyl compound completed the synthesis of MK-7.
  • Scheme 5b is an alternative use of the Kumada coupling strategy using a prohydroxyl reactant during the Kumada coupling stage to readily afford a reactive X group for further reaction.
  • the inventors also envisage the use of Suzuki coupling chemistry to effect the menaquinone synthesis.
  • the Suzuki reaction involves the reaction of an aryl- or vinyl-boronic acid with an aryl- or vinyl-halide catalyzed by a palladium(0) complex.
  • the naphthoquinone bromide can be converted into a boronic acid using known techniques, e.g. by transmetallation with lithium.
  • this boronic acid can be coupled with a suitable halide, triflate or tosylate under Suzuki conditions, i.e. using Pd(0) catalysis.
  • the palladium catalyst is preferably 4-coordinate, and usually involves phosphine supporting groups, e.g. tetrakis(triphenylphosphine)palladium(0).
  • Scheme 6 shows the Suzuki coupling in action.
  • Suzuki chemistry see Suzuki, A. Pure Appl. Chem. 1991, 63, 419-422 .
  • reaction achieved in the first and second aspects of the invention i.e. a Kumada or Suzuki coupling reaction can yield only a relatively short side chain which can then be built up to form a compound of formula (I).
  • a Kumada or Suzuki coupling reaction can yield only a relatively short side chain which can then be built up to form a compound of formula (I).
  • Suzuki or any other chemistry can be used.
  • the invention further comprises a process for the preparation of a compound of formula (I) comprising (i) reacting a compound of formula (II) or (IV) with a compound of formula (III) as hereinbefore defined;
  • the catalyst used here is chosen depending on the reaction in question, e.g. Pd(0) for a Suzuki coupling, Cu(II), Ni (II) or Pd(0) for Kumada.
  • the invention further comprises a process for the preparation of a compound of formula (I) comprising (i) reacting a compound of formula (II) or (IV) with a compound of formula (III) as hereinbefore defined;
  • MK-7 is produced especially where 2 units come from compound (III), 4 units from compound (V) or (VI) (the 7th being formed by the reaction). This is the most preferred process of the invention. The preferred process is therefore wherein any leaving group may be substituted for Br (e.g. other halogens, tosylate, mesylate etc).
  • a benefit of preparing MK-7 using this "2+5" strategy is that the selenium dioxide reduction step used to form the napthoquinone reactant takes place more readily on a naphthoquinone carrying on 2 isoprenoid units than on a longer chain molecule. This "2+5" method also gives better stereochemistry and has been found to allow the formation of solid, in particular crystalline MK-7.
  • the inventors have realised that different side chains can be prepared using a double Biellmann coupling (or triple Bielmann etc). Initially, therefore two shorter chain molecules can be combined. By using appropriate protection strategies, the coupled species can then be deprotected to reveal an alcohol which can be converted to phenythio or phenylsulfonyl substituted compounds ready for a second Biellmann coupling. In this way, the isoprenoid units needed to form the complete side chain of a long menaquinone can be joined together from shorter starting blocks.
  • Reduction of all phenythio or phenylsulfonyl substituted compounds present can take place as a final step to yield a side chain suitable for coupling to a naphthoquinone related molecule, e.g. using Kumada or Suzuki chemistry.
  • This reaction is highly flexible and allows the formation of side chains for menaquinones such as MK-6, MK-7, MK-8, MK-9, MK-10 and MK-11.
  • the invention provides a process for the preparation of a compound comprising an isoprenoid repeating unit comprising (i) reacting a compound of formula with a compound
  • the Biellmann reaction can be carried out on a molecule in which the naphthoquinone ring (or a protected analogue thereof) is, present. It may be therefore that the phenylthioether required in the Biellmann reaction already carries a naphthoquinone group.
  • the side chain terminus is converted to a hydroxyl using selenium dioxide and this hydroxyl can be converted to a halide and coupled with phenythio or phenylsulfonyl substituted derivatives using chemistry described above.
  • the invention provides a process for the preparation of a compound of formula (I) as hereinbefore defined comprising (i) reacting a compound of formula (II) or (IV) with a compound of formula (III) in the presence of a copper, nickel or palladium catalyst;
  • This reaction can also be carried out using other R groups to protect the naphthoquinone and again it will be appreciated that the sum of the various n values of the starting materials will add up to the value of n in the compound of formula (I) taking into account any units formed in the reactions.
  • Typical solvents of use in the processes of the invention include, THF, DCM, DMSO, ethyl acetate, alcohols, amines, ethers, hydrocarbons, aryl solvents and so on. Where reactions need to be cooled, ice baths, dry ice baths or cooling machines can be used, for example.
  • the final products of the formula (1) formed by the processes of the invention are generally known compounds and have well documented therapeutic applications.
  • the formed compounds may therefore be formulated as pharmaceutically acceptable compositions.
  • the compounds of formula (I) have utility in the treatment of osteoporosis, cancer or cardio-vascular disease.
  • the compounds may also be used as vitamin supplements or in any other known application of vitamin K, e.g. for injection into new-born infants to aid blood clotting.
  • the MK products achieved are highly pure. They have excellent stereochemical integrity and can be manufactured as solids as opposed to oils.
  • the MK-n compounds manufactured according to the invention can be crystalline, especially crystalline MK-7.
  • Benzyloxyfarnesol was prepared as described in the literature ( Naruta, Y. J. Org. Chem. (1980), 45, 4097 .
  • reaction mixture was poured into ice-water (600 ml) and the aqueous layer separated and extracted with ether (3x300 ml). The combined organic extracts were washed with ice-cold NaHCO 3 (400 ml) and brine (400 ml), dried (Na 2 SO 4 ), filtered and concentrated to give 25.47 g (98%) of the product as a colorless oil used directly in the next step.
  • Heptaprenol was converted to heptaprenyl bromide as described above or by applying PBr 3 in DCM or ether.
  • the orange mixture was stirred at 0 °C for 40 min. and at room temperature for 16.5 h over night.
  • the yellow mixture was poured into 100 ml ice water.
  • the layers were separated and the aqueous layer was extracted with CH 2 Cl 2 .
  • the combined organic extracts were washed with ice water, dried over Na 2 SO 4 , filtered and concentrated in vacuo by rotary evaporation at 40 °C to give 8.50 g of yellow oil. It was purified by dry flash.
  • the crude product was further purified by flash column chromatography on SiO 2 using a mixture of heptane:EtOAc (9/1 v/v) as eluent to give a yellow oil (1.55 g, 1.93 mmol, 67%).

Claims (12)

  1. Verfahren zur Herstellung einer Verbindung der Formel (I)
    Figure imgb0083
     das einen Schritt umfasst, bei dem (i) eine Verbindung der Formel (II) mit einer Verbindung der Formel (III) umgesetzt wird
    Figure imgb0084
     wobei R eine Alkylgruppe darstellt;
    LG eine Abgangsgruppe darstellt;
    m eine ganze Zahl von 0 bis 8 ist;
    n eine ganze Zahl von 0 bis 9 ist; und
    X Wasserstoff, Halid, Hydroxyl oder geschütztes Hydroxyl darstellt;
    in Gegenwart eines Palladiumkatalysators.
  2. Verfahren zur Herstellung einer Verbindung der Formel (I)
    Figure imgb0085
     das einen Schritt umfasst, bei dem (i) eine Verbindung der Formel (IV)
    Figure imgb0086
     wo R eine Alkylgruppe darstellt; mit einer Verbindung der Formel (III) umgesetzt wird
    Figure imgb0087
     wobei R eine Alkylgruppe darstellt;
    LG eine Abgangsgruppe darstellt;
    m eine ganze Zahl von 0 bis 8 ist;
    n eine ganze Zahl von 0 bis 9 ist; und
    X Wasserstoff, Halid, Hydroxyl oder geschütztes Hydroxyl darstellt;
    in Gegenwart eines Palladium (0) katalysators.
  3. Verfahren zur Herstellung einer Verbindung der Formel (I) wie in Anspruch 1 oder 2 beansprucht, das (i) das Umsetzen einer Verbindung der Formel (II) oder (IV) mit einer Verbindung der Formel (III) wie in Anspruch 1 oder 2 beansprucht umfasst;
    (iii) falls erforderlich, das Umwandeln von X in eine Abgangsgruppe;
    (iv) das Umsetzen mit einer Verbindung (V) oder (VI)
    Figure imgb0088
     oder
    Figure imgb0089
     wobei m unabhängig wie zuvor definiert vorliegt, in Gegenwart einer Base;
    (v) das Reduzieren der -SO2Ph- oder SPh-Gruppe in der resultierenden Verbindung zu einem Hydrid; sowie
    (vi) das Umwandeln des zweifach geschützten Naphthochinons in ein Naphthochinon.
  4. Verfahren wie in Anspruch 3 beansprucht, wobei Schritt (vi) unter Verwendung von Ceriumammoniumnitrat (CAN) erreicht wird.
  5. Verfahren wie in Anspruch 3 beansprucht, wobei die Reaktion einer Verbindung der Formel (II) oder (IV) mit einer Verbindung der Formel (III) zu der Verbindung (I') führt, bei der X Wasserstoff darstellt.
    Figure imgb0090
  6. Verfahren wie in Anspruch 5 beansprucht, wobei ein endständiger Wasserstoff (d.h. der Wasserstoff an der X-Position) zu Hydroxyl umgewandelt wird unter Verwendung von Selendioxid und daraufhin in eine Abgangsgruppe umgewandelt wird, z.B. ein Halid, um dadurch Schritt (iv) zu erleichtern.
  7. Verfahren zur Herstellung einer Verbindung der Formel (I) wie in Anspruch 1 oder 2 beansprucht, das (i) das Umsetzen einer Verbindung der Formel (II) oder (IV) mit einer Verbindung der Formel (III) wie in Anspruch 1 oder 2 beansprucht umfasst;
    (iii) falls erforderlich, das Umwandeln von X in eine Abgangsgruppe, um die folgende Verbindung zu bilden
    Figure imgb0091
     wobei LG, R und m wie zuvor definiert vorliegen;
    (iv) das Umsetzen mit einer Verbindung (V) oder (VI)
    Figure imgb0092
     oder
    Figure imgb0093
     wobei m unabhängig wie zuvor definiert vorliegt, in Gegenwart einer Base, um (I") zu bilden
    Figure imgb0094
  8. Verfahren wie in Anspruch 7 beansprucht, wobei die Verbindung der Formel (I") wie folgt vorliegt
    Figure imgb0095
  9. Verbindungen
    Figure imgb0096
     und
    Figure imgb0097
  10. Verfahren zur Herstellung einer Verbindung der Formel (I) wie in Anspruch 1 oder 2 definiert,
    Figure imgb0098
     das (i) das Umsetzen einer Verbindung der Formel (II) oder (IV) mit einer Verbindung der Formel (III) in Gegenwart eines Palladiumkatalysators wie in Anspruch 1 oder 2 definiert umfasst;
    (iii) das Umwandeln von X in eine SPh- oder -SO2Ph-Gruppe, um die Verbindung (VII) zu bilden
    Figure imgb0099
     wobei m unabhängig wie zuvor definiert vorliegt;
    (iv) das Deprotonieren (alpha zum Schwefel) und das Umsetzen mit einer Verbindung
    Figure imgb0100
     wobei m unabhängig wie zuvor definiert vorliegt;
    (v) das Reduzieren des Phenylthioethers oder von - SO2Ph zu Wasserstoff; sowie
    (vi) das Umwandeln des zweifach geschützten Naphthochinons in einen Naphthochinonring.
  11. Verfahren zur Herstellung einer Verbindung der Formel (I) wie in Anspruch 1 oder 2 beansprucht
    Figure imgb0101
     das (i) das Umsetzen einer Verbindung der Formel (II) oder (IV) mit einer Verbindung der Formel (III) wie in Anspruch 1 oder 2 beansprucht umfasst;
    (iii) falls erforderlich, das Umwandeln von X in eine Abgangsgruppe;
    (iv) das Umsetzen mit einer Verbindung
    Figure imgb0102
     oder
    Figure imgb0103
     wobei m unabhängig wie zuvor definiert vorliegt,
    in Gegenwart eines Ni, Cu oder Pd Katalysators; sowie
    (v) das Umwandeln des zweifach geschützten Naphthochinons in ein Naphthochinon.
  12. Verfahren wie in einem der vorherigen Ansprüche beschrieben, wobei die Verbindung der Formel (I) wie folgt vorliegt
    Figure imgb0104
EP09785160.4A 2008-09-24 2009-09-24 Verfahren zur herstellung von vitamin k2 Active EP2346806B1 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PL09785160T PL2346806T3 (pl) 2008-09-24 2009-09-24 Sposób wytwarzania witaminy k2
DK15193746.3T DK3018116T3 (da) 2008-09-24 2009-09-24 Vitamin k2-intermediater
PL15193746T PL3018116T3 (pl) 2008-09-24 2009-09-24 Związki pośrednie witaminy K
EP15193746.3A EP3018116B1 (de) 2008-09-24 2009-09-24 Vitamin k2-zwischenprodukte

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0817528.3A GB0817528D0 (en) 2008-09-24 2008-09-24 Process
PCT/GB2009/002282 WO2010035000A1 (en) 2008-09-24 2009-09-24 Process for the preparation of vitamin k2

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP15193746.3A Division EP3018116B1 (de) 2008-09-24 2009-09-24 Vitamin k2-zwischenprodukte
EP15193746.3A Division-Into EP3018116B1 (de) 2008-09-24 2009-09-24 Vitamin k2-zwischenprodukte

Publications (2)

Publication Number Publication Date
EP2346806A1 EP2346806A1 (de) 2011-07-27
EP2346806B1 true EP2346806B1 (de) 2016-01-06

Family

ID=39952163

Family Applications (2)

Application Number Title Priority Date Filing Date
EP09785160.4A Active EP2346806B1 (de) 2008-09-24 2009-09-24 Verfahren zur herstellung von vitamin k2
EP15193746.3A Revoked EP3018116B1 (de) 2008-09-24 2009-09-24 Vitamin k2-zwischenprodukte

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP15193746.3A Revoked EP3018116B1 (de) 2008-09-24 2009-09-24 Vitamin k2-zwischenprodukte

Country Status (7)

Country Link
US (3) US9012693B2 (de)
EP (2) EP2346806B1 (de)
CN (2) CN104725205A (de)
DK (2) DK2346806T3 (de)
GB (3) GB0817528D0 (de)
PL (2) PL3018116T3 (de)
WO (2) WO2010034999A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11912654B2 (en) 2021-09-03 2024-02-27 Synergia Life Sciences Pvt. Ltd. Process for stereospecific synthesis of vitamin K2 and its novel intermediates

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0817528D0 (en) * 2008-09-24 2008-10-29 Syntavit As Process
GB201004876D0 (en) * 2010-03-23 2010-05-05 Syntavit As Process for the preparation of vitamin K2
CN102485709B (zh) * 2010-12-01 2014-10-22 天津康鸿医药科技发展有限公司 维生素k2类化合物的制备方法
GB201203705D0 (en) * 2012-03-02 2012-04-18 Kappa Bioscience As Prodrugs
PL401195A1 (pl) 2012-10-12 2014-04-14 Instytut Farmaceutyczny Sposób wytwarzania witaminy K2 w formie MK-7
US9464021B2 (en) 2013-11-01 2016-10-11 Dilip S. Mehta Method of preparation of stereospecific quinone derivatives
BR112016025876B1 (pt) 2014-05-05 2023-03-14 Basf Se Composição, processo para preparar uma composição, e, produto
CN104058946B (zh) * 2014-06-30 2017-02-08 重庆第二师范学院 具有抗肿瘤活性的大黄素过渡金属配合物、制备方法及其应用
PL424875A1 (pl) * 2018-03-12 2019-09-23 Vitasynth Spółka Z Ograniczoną Odpowiedzialnością Sposób syntezy witaminy K2
SG11202012070YA (en) 2018-06-08 2021-01-28 Epizon Pharma Inc Methods and compositions for preventing or treating tissue calcification
AU2019282421A1 (en) 2018-06-08 2021-01-07 Epizon Pharma, Inc. Methods and compositions for preventing or treating calciphylaxis
US10822295B2 (en) 2018-09-12 2020-11-03 Epizon Pharma, Inc. Menaquinol compositions and methods of treatment
PL243187B1 (pl) 2020-07-16 2023-07-10 Vitasynth Spolka Z Ograniczona Odpowiedzialnoscia Sposób i związki pośrednie do otrzymywania menachinonu MK-7
GB202103137D0 (en) 2021-03-05 2021-04-21 Kappa Bioscience As Process for the preparation of vitamin K2 and novel intermediates
WO2023031841A1 (en) * 2021-09-03 2023-03-09 Synergia Life Sciences Pvt. Ltd. A process for the stereospecific synthesis of vitamin k2 and its intermediates

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4159993A (en) * 1975-04-07 1979-07-03 The Regents Of The University Of California 3-Metallo substituted naphthalenes
US4234746A (en) * 1975-01-13 1980-11-18 The Regents Of The University Of California Metallo-substituted naphthalene
US4089873A (en) 1975-01-13 1978-05-16 The Regents Of The University Of California Preparation of menaquinones
CA1091680A (en) 1976-10-19 1980-12-16 Shinji Terao Method for production of quinones
FR2435466A1 (fr) 1978-08-02 1980-04-04 Kuraray Co Derives de l'hydroquinone et leur procede de preparation
JPS5640651A (en) 1979-09-12 1981-04-16 Takeda Chem Ind Ltd Quinone compound and its preparation
JPS5795932A (en) 1980-12-05 1982-06-15 Kuraray Co Ltd Preparation of hydroquinone derivative
FR2508451A1 (fr) * 1981-06-26 1982-12-31 Interox Procede pour la fabrication d'epoxydes
US5229385A (en) 1986-01-30 1993-07-20 Takeda Chemical Industries, Ltd. Quinone derivatives, their production and use
JPH1132787A (ja) * 1997-07-23 1999-02-09 Kikkoman Corp メナキノン−７含有物の製造方法及びそれを含有する飲食品
JP2001136959A (ja) * 1999-11-17 2001-05-22 Hiroyuki Sumi 枯草菌菌体および／またはその産生物を含む培養物、これに由来する水溶性ビタミンｋ誘導体、これらを含む医薬、食品および飼料ならびにこれらの製造方法
JP2001204400A (ja) * 2000-01-19 2001-07-31 Hiroyuki Sumi メナキノン−７生産
JP3431573B2 (ja) * 2000-05-26 2003-07-28 三和酒類株式会社 メナキノン−７の製造方法
JP3783915B2 (ja) * 2000-06-15 2006-06-07 洋行 須見 納豆菌由来の生理活性物質
JP2002058468A (ja) * 2000-08-18 2002-02-26 Nariwa Ozeki Shuzo Kk ビタミンｋ含有酒類およびその製造方法
SI1803820T1 (sl) * 2005-12-29 2009-10-31 Gnosis Spa Postopek za pripravo vitamina k2
US20080220094A1 (en) * 2006-11-01 2008-09-11 Wyeth Compositions and methods for the treatment and/or prevention of osteoporosis
CN101029003A (zh) * 2007-04-13 2007-09-05 北京化工大学 一种用茄呢醇合成维生素k2的方法
GB0817528D0 (en) * 2008-09-24 2008-10-29 Syntavit As Process
PL401195A1 (pl) 2012-10-12 2014-04-14 Instytut Farmaceutyczny Sposób wytwarzania witaminy K2 w formie MK-7

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11912654B2 (en) 2021-09-03 2024-02-27 Synergia Life Sciences Pvt. Ltd. Process for stereospecific synthesis of vitamin K2 and its novel intermediates

Also Published As

Publication number Publication date
US20110207967A1 (en) 2011-08-25
EP2346806A1 (de) 2011-07-27
GB0916849D0 (en) 2009-11-04
EP3018116B1 (de) 2020-10-28
DK2346806T3 (en) 2016-02-08
WO2010034999A1 (en) 2010-04-01
GB2464797A (en) 2010-05-05
US10472314B2 (en) 2019-11-12
DK3018116T3 (da) 2021-01-25
US20170283354A1 (en) 2017-10-05
US20150210620A1 (en) 2015-07-30
GB2463981A (en) 2010-04-07
PL3018116T3 (pl) 2021-06-28
GB0817528D0 (en) 2008-10-29
CN102216248A (zh) 2011-10-12
WO2010035000A8 (en) 2011-04-14
CN104725205A (zh) 2015-06-24
GB0916848D0 (en) 2009-11-04
GB2463981B (en) 2011-05-25
WO2010035000A1 (en) 2010-04-01
US9012693B2 (en) 2015-04-21
PL2346806T3 (pl) 2016-06-30
EP3018116A1 (de) 2016-05-11

Similar Documents

Publication Publication Date Title
EP2346806B1 (de) Verfahren zur herstellung von vitamin k2
WO2011117324A2 (en) Process for the preparation of vitamin k2
CN103717585B (zh) 贝前列素的生产方法
CA2026671C (en) 24-homo vitamin d derivatives, process for their production and pharmaceutical preparations obtained therefrom
EP2917171B1 (de) Verfahren zur herstellung von vitamin k2 vom mk-7-typ
CN114269717A (zh) 催化大麻素方法和前体
WO2013023327A1 (zh) 25-羟基维生素d2系列药物侧链及其制备方法
JPS646189B2 (de)
CN1181030C (zh) 抗肿瘤类新药沙尔威辛的全合成方法
KR100514494B1 (ko) 코엔자임 큐와 비타민 케이의 합성에 효율적으로 사용되는알릴릭 설폰기를 함유하는 파라-하이드로퀴논 화합물의합성 방법
JP2003327574A (ja) ショウガオール類の製造方法および合成用中間体
EP0171320A1 (de) Herstellungsverfahren von ungesättigten, in alpha-chlorierten Verbindungen von zwei in beta-Stellung elektronenanziehenden Gruppen
WO2019016315A1 (en) PROCESS FOR PRODUCING 3,7-DIMETHYL-9- (2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-YL) -NONA-2Z, 7E-DIEN-4-YNE-1,6-DIOL
FR2684373A1 (fr) Nouveaux intermediaires de preparation de vitamines a et e et des carotenouides.
WO2022184938A1 (en) Process for the preparation of vitamin k2 and novel intermediates
KR20060117430A (ko) 코엔자임 Ｑｎ의 제조방법 및 그의 중간체
Sidoryk et al. Process of vitamin K 2 derivatives preparation
CN108840793A (zh) 一种应用模拟移动床色谱制备γ-崖柏素的方法
JP3589591B2 (ja) ポリハロゲン化モノテルペン並びにハロモンの製造方法
JPH0912502A (ja) 新規なトランスヒドリンダン誘導体
KR20050071927A (ko) 카로티노이드 중간체 화합물, 그 제조방법 및 이를 이용한카로티노이드 화합물, 아스타잔틴 및 아스타신의 제조방법

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110421

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20121109

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 41/18 20060101ALI20131101BHEP

Ipc: C07C 43/23 20060101ALI20131101BHEP

Ipc: C07C 41/26 20060101ALI20131101BHEP

Ipc: C07C 41/30 20060101ALI20131101BHEP

Ipc: C07C 41/22 20060101ALI20131101BHEP

Ipc: C07C 317/18 20060101ALI20131101BHEP

Ipc: C07C 43/215 20060101ALI20131101BHEP

Ipc: C07C 315/04 20060101ALI20131101BHEP

Ipc: C07C 46/02 20060101AFI20131101BHEP

Ipc: C07C 43/225 20060101ALI20131101BHEP

Ipc: C07C 50/14 20060101ALI20131101BHEP

INTG Intention to grant announced

Effective date: 20131126

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SKATTEBOL, LARS

Inventor name: SANDBERG, MARCEL

Inventor name: AUKRUST, INGGER, RIEDUN

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 317/18 20060101ALI20150216BHEP

Ipc: C07C 43/225 20060101ALI20150216BHEP

Ipc: C07C 43/215 20060101ALI20150216BHEP

Ipc: C07C 319/20 20060101ALI20150216BHEP

Ipc: C07C 41/26 20060101ALI20150216BHEP

Ipc: C07C 41/30 20060101ALI20150216BHEP

Ipc: C07C 41/18 20060101ALI20150216BHEP

Ipc: C07C 50/14 20060101ALI20150216BHEP

Ipc: C07C 41/22 20060101ALI20150216BHEP

Ipc: C07C 46/02 20060101AFI20150216BHEP

Ipc: C07C 17/16 20060101ALI20150216BHEP

Ipc: C07C 43/23 20060101ALI20150216BHEP

Ipc: C07C 315/04 20060101ALI20150216BHEP

INTG Intention to grant announced

Effective date: 20150305

RIN1 Information on inventor provided before grant (corrected)

Inventor name: AUKRUST, INGGER, RIEDUN

Inventor name: SKATTEBOL, LARS

Inventor name: SANDBERG, MARCEL

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20160202

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 768712

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160215

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602009035663

Country of ref document: DE

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20160106

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 768712

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160106

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160407

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160106

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160106

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160106

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160106

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160506

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160506

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160106

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160106

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160106

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602009035663

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160106

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160106

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160106

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160106

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160106

26N No opposition filed

Effective date: 20161007

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160106

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160106

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160406

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160106

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160930

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160924

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160106

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20090924

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160106

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160106

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160930

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602009035663

Country of ref document: DE

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230518

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20230627

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20230816

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NO

Payment date: 20230911

Year of fee payment: 15

Ref country code: IE

Payment date: 20230710

Year of fee payment: 15

Ref country code: GB

Payment date: 20230803

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20230810

Year of fee payment: 15

Ref country code: PL

Payment date: 20230712

Year of fee payment: 15

Ref country code: FR

Payment date: 20230808

Year of fee payment: 15

Ref country code: DE

Payment date: 20230802

Year of fee payment: 15